INFO60
SpotlightTopics60sNEWQuizLogin
IndiaAI & TechBusinessTechnologySportsEntertainmentHealthScienceWorld
INFO60

Know more. Read less. What matters, fast.

Company

  • About
  • Contact
  • Editorial Policy
  • Corrections
  • Our desks
  • Publishers

Legal

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Account

  • Delete Account
  • Spotlight
  • Quick Cards
  • Topics
  • Web Stories
  • Hindi News

Free. One email a day. Unsubscribe anytime.

Editions

  • India
  • United States
  • United Kingdom
  • Canada
  • Australia
  • UAE & Gulf
  • Singapore
  • Hindi
  • All countries
© 2026 Info60. All rights reserved.
Home›business›New NHS cancer drug Enhertu is 'bittersweet' for Crawley widower
business

New NHS cancer drug Enhertu is 'bittersweet' for Crawley widower

By Info60 UK Desk•Summary of reporting by BBC•Sep 17, 2026•0 views•
New NHS cancer drug Enhertu is 'bittersweet' for Crawley widower
Fionnuala Quinlan-Bennett died in June, months before Enhertu was greenlit for the NHS in England.
A man who lost his wife to breast cancer has described the drug which could have extended her life finally being made available on the NHS in England as "bittersweet". Fionnuala Quinlan-Bennett, a primary school teacher from Crawley, West Sussex, die... [1345 chars]
Read Full Article

Share this story

Report an error

Up next

Related Stories

The AI telling farmers when to harvest

The AI telling farmers when to harvest

BBC Business

Vape prices to rise as new tax takes effect

Vape prices to rise as new tax takes effect

BBC Business

Energy bills are going up - here's what you can do about it

Energy bills are going up - here's what you can do about it

BBC Business

Flydubai passenger describes putting attacker in chokehold after cockpit stabbing

Flydubai passenger describes putting attacker in chokehold after cockpit stabbing

yahoo.com

Netherlands ditches wealth tax over exodus fears

Netherlands ditches wealth tax over exodus fears

The Telegraph

Comments (0)

Please login to comment

Login
💬

No comments yet. Be the first to comment!